BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 33682732)

  • 21. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders.
    Jellinger KA
    Biochim Biophys Acta; 2009 Jul; 1792(7):730-40. PubMed ID: 18718530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determinants of seeding and spreading of α-synuclein pathology in the brain.
    Henrich MT; Geibl FF; Lakshminarasimhan H; Stegmann A; Giasson BI; Mao X; Dawson VL; Dawson TM; Oertel WH; Surmeier DJ
    Sci Adv; 2020 Nov; 6(46):. PubMed ID: 33177086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats.
    Van Den Berge N; Ferreira N; Gram H; Mikkelsen TW; Alstrup AKO; Casadei N; Tsung-Pin P; Riess O; Nyengaard JR; Tamgüney G; Jensen PH; Borghammer P
    Acta Neuropathol; 2019 Oct; 138(4):535-550. PubMed ID: 31254094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuropathological evidence of body-first vs. brain-first Lewy body disease.
    Borghammer P; Horsager J; Andersen K; Van Den Berge N; Raunio A; Murayama S; Parkkinen L; Myllykangas L
    Neurobiol Dis; 2021 Dec; 161():105557. PubMed ID: 34763110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Ascendance of Abnormal α-synuclein Fibrils Through the Vagal Nerve in Parkinson's Disease].
    Ohno K; Hirayama M
    Brain Nerve; 2022 Aug; 74(8):979-984. PubMed ID: 35941794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
    Jimenez-Ferrer I; Bäckström F; Dueñas-Rey A; Jewett M; Boza-Serrano A; Luk KC; Deierborg T; Swanberg M
    Brain Behav Immun; 2021 Jan; 91():369-382. PubMed ID: 33223048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The concept of alpha-synuclein as a prion-like protein: ten years after.
    Steiner JA; Quansah E; Brundin P
    Cell Tissue Res; 2018 Jul; 373(1):161-173. PubMed ID: 29480459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.
    Wilson H; Dervenoulas G; Pagano G; Koros C; Yousaf T; Picillo M; Polychronis S; Simitsi A; Giordano B; Chappell Z; Corcoran B; Stamelou M; Gunn RN; Pellecchia MT; Rabiner EA; Barone P; Stefanis L; Politis M
    Lancet Neurol; 2019 Aug; 18(8):748-759. PubMed ID: 31229470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates.
    Arotcarena ML; Dovero S; Prigent A; Bourdenx M; Camus S; Porras G; Thiolat ML; Tasselli M; Aubert P; Kruse N; Mollenhauer B; Trigo Damas I; Estrada C; Garcia-Carrillo N; Vaikath NN; El-Agnaf OMA; Herrero MT; Vila M; Obeso JA; Derkinderen P; Dehay B; Bezard E
    Brain; 2020 May; 143(5):1462-1475. PubMed ID: 32380543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
    Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
    Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The link between the gut microbiota and Parkinson's Disease: A systematic mechanism review with focus on α-synuclein transport.
    Nielsen SD; Pearson NM; Seidler K
    Brain Res; 2021 Oct; 1769():147609. PubMed ID: 34371014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parkinson's disease outside the brain: targeting the autonomic nervous system.
    Sharabi Y; Vatine GD; Ashkenazi A
    Lancet Neurol; 2021 Oct; 20(10):868-876. PubMed ID: 34536407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
    Jellinger KA
    Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double-Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing α-Synuclein.
    Schidlitzki A; Stanojlovic M; Fournier C; Käufer C; Feja M; Gericke B; Garzotti M; Welford RWD; Steiner MA; Angot E; Richter F
    Mov Disord; 2023 Jun; 38(6):1044-1055. PubMed ID: 37050861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tau accelerates α-synuclein aggregation and spreading in Parkinson's disease.
    Pan L; Li C; Meng L; Tian Y; He M; Yuan X; Zhang G; Zhang Z; Xiong J; Chen G; Zhang Z
    Brain; 2022 Oct; 145(10):3454-3471. PubMed ID: 35552614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatic copy number gains of α-synuclein (SNCA) in Parkinson's disease and multiple system atrophy brains.
    Mokretar K; Pease D; Taanman JW; Soenmez A; Ejaz A; Lashley T; Ling H; Gentleman S; Houlden H; Holton JL; Schapira AHV; Nacheva E; Proukakis C
    Brain; 2018 Aug; 141(8):2419-2431. PubMed ID: 29917054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.